JACC: Cardiooncology

Papers
(The TQCC of JACC: Cardiooncology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Full Issue PDF126
Editorial Board120
Full Issue PDF109
Full Issue PDF98
Priorities in Cardio-Oncology96
Balancing Promise and Evidence72
Hormonal Therapy and Cardiovascular Health71
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy69
Atrial Fibrillation in Patients With Cancer68
Full Issue PDF68
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients62
Epigenomics of Cardio-Oncology59
Cardiovascular Safety in Oncology Clinical Trials58
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque56
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part55
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes55
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy53
Cardiac Risk Stratification Before Lung Cancer Radiation51
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients50
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors49
Full Issue PDF46
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD45
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy43
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA40
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis38
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms38
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis37
Frailty37
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma35
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy34
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-201931
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)31
Editorial Board/Officers Page31
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD30
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors30
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients30
Clonal Hematopoiesis in Cancer and Cardiovascular Disease30
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis30
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer28
Permissive Cardiotoxicity26
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance26
Cancer Immunotherapy Beyond Checkpoint Blockade24
Full Issue PDF24
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer24
Editorial Board24
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS23
Developing a Model for Cross-Institutional Educational Collaborations22
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO22
Leveling Up22
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy22
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation22
Endothelin-122
Reply21
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research21
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity21
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity21
Quality-of-Care Measures for Cardio-Oncology21
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge20
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity20
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK20
The United Kingdom’s First Cardio-Oncology Service20
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy20
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction20
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy20
Vascular Complications of Atrial Fibrillation in Patients With Cancer20
Low QRS Voltages in Cardiac Amyloidosis19
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients18
CHA2DS2-VASc Score in Cardio-Oncology18
Full Issue PDF18
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent18
Fluoropyrimidine Therapy in Gastrointestinal Cancer18
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction18
Imaging Immune Checkpoint Inhibitor Myocarditis17
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity17
Diet and Prevention of Cardiovascular Disease and Cancer17
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer17
High-Sensitivity Troponin I17
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction17
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy17
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.17
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer16
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia16
To Adjudicate or Not Adjudicate16
Full Issue PDF15
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity15
How to Perform Hematopoietic Stem Cell Transplantation15
Cardiovascular Risk Assessment in Patients With Kidney Cancer15
ABSTRACT WITHDRAWN14
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors14
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING14
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors14
Hearts on the Minds of Oncologists14
FULL ISSUE PDF14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors13
Author Index13
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer12
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?12
Cancer Therapy–Related Cardiac Dysfunction12
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?12
Cardiovascular Considerations After Cancer Therapy12
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy11
JACC: CardioOncology11
PALLIATIVE RESECTION OF A CARDIAC SARCOMA11
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors11
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT11
Guiding Treatment With Recovered CTRCD11
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness11
(Less) Time and Energy11
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY11
Navigating the Uncharted10
Reply10
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity10
Reply10
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer10
Clinical Practice Guidelines in Cardio-Oncology10
Preventing Cancer Therapy–Related Cardiotoxicity10
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction10
The Cause of Death in Patients With Cancer10
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors10
Reply10
Cardiovascular Care After Cancer10
Addressing the Overlooked10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies10
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer10
Full Issue PDF10
When Clot Is Tumor9
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA9
The ESC Cardio-Oncology Guidelines9
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology9
Reply9
Editorial Board/Officers Page9
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB9
Reply9
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population9
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN9
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation9
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy9
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients8
Learning From Trials8
Assessing STEMI Outcomes in Patients With Cancer8
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients8
Cancer Diagnosis, Physical Activity, and Heart Disease Risk8
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors8
Overcoming LGBTQI+ Disparities in Cardio-Oncology8
Full Issue PDF8
Editorial Board8
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy8
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients8
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION8
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity8
0.078037023544312